Wockhardt Reports Q2 FY27 Financial Results and Novel Antibiotic Portfolio Progress
Wockhardt Ltd 路 Press Release 路 02 Nov 2026, 10:30 pm
Wockhardt Reports Q2 FY27 Financial Results and Novel Antibiotic Portfolio Progress Wockhardt reported Q2 FY27 revenue of Rs 969 Cr, up 24% YoY, while EBITDA rose 3% YoY to Rs 165 Cr (Rs 201 Cr excluding pre-Zaynich launch expenses). PAT stood at Rs 73 Cr versus Rs 82 Cr in Q2 FY26. Biotech operations surged 68% YoY to Rs 252 Cr, driven by Emerging Markets growth of 52% YoY to Rs 310 Cr. Key pipeline milestones include US FDA approval for Zaynich, EMA review progression, and the completion of Phase 2/3 trials for Foviscu.
Original exchange filing (PDF)
More announcements from Wockhardt Ltd
- Pursuant to Regulation 30 of SEBI LODR Regulations, 2015 read with Schedule III thereto, we wish to inform you that Mr. Vinesh Kumar Jairath (DIN: 00391684) has completed his second consecutive .... 路 09 Nov 2026
- Please refer the attachment. 路 02 Nov 2026
- Appointment of Mr. Sumit Garg as Chief Digital & Information Officer as Senior Management Personnel of the Company. 路 02 Nov 2026
- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of directors at its meeting held today, i.e. 2nd November, 2026, inter-alia, .... 路 02 Nov 2026
- Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no: WOCK/SEC/SE/2026-27/042 dated 27th October, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 2nd November, 2026, inter-alia, has approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year 路 02 Nov 2026
- Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting .... 路 02 Nov 2026
- We wish to inform that Share Allotment Committee of Board of Directors of the Company has allotted 20000 equity shares of face value of Rs 5 each on 27th October, 2026 pursuant to exercise .... 路 27 Oct 2026
- WOCKHARDT LIMITED has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 02 Nov 2026
